Share

January 2020; 7 (1) Correction

IL6 receptor358Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis

First published December 5, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000650
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
254

Share

See original article:

In the article “IL6 receptor358Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis” by Wosiski-Kuhn et al.,1 first published online October 14, 2019, the y-axis label in figure 1C should be “Serum sIL6R (ng/mL).” In figure 1E, the y-axis label should be “Serum sgp130 (ng/mL).” In figure 2A, the y-axis label should be “Serum sIL6R (ng/mL).” The editorial office regrets the errors.

Reference

  1. 1.↵
    1. Wosiski-Kuhn M,
    2. Robinson M,
    3. Strupe J, et al
    . IL6 receptor358Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm 2019;6:e631. doi: 10.1212/NXI.0000000000000631.
    OpenUrlAbstract/FREE Full Text

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Alert Me

Recommended articles